Dr. Cerny is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Dept of Hematologyoncology
Worcester, MA 01655Phone+1 774-442-3903Fax+1 774-442-6715
Summary
- Dr. Jan Cerny is a hematologist/oncologist practicing in Worcester, MA and is affiliated with UMass Memorial Medical Center. He received his medical degree from Charles University Faculty of Medicine and has been in practice 18 years. He specializes in hematologic oncology and is experienced in leukemia, myeloid malignancies, myelodysplasia, myelofibrosis, lymphoma and multiple myeloma.He performs bone marrow transplants as well.
Education & Training
UMass Chan Medical SchoolFellowship, Hematology and Medical Oncology, 2006 - 2009- UMass Chan Medical SchoolResidency, Internal Medicine, 2003 - 2006
Karlovy University FOMClass of 1999
Certifications & Licensure
MA State Medical License 2006 - 2026- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle and Connolly, 2017
- Regional Top Doctor Castle Connoly, 2015
- Regional Top Doctor Castle Connolly, 2014
- Join now to see all
Clinical Trials
- Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML. Start of enrollment: 2010 Jan 01
- Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth Start of enrollment: 2009 Sep 01
- Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission Start of enrollment: 2012 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 19 citationsMaintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple MyelomaRobert F. Cornell, Anita D'Souza, Adetola A. Kassim, Luciano J. Costa, Racquel Innis-Shelton
Biology of Blood and Marrow Transplantation. 2017-02-01 - 7 citationsRisk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.Kamal Menghrajani, Alexandra Gomez-Arteaga, Rafael Madero-Marroquin, Mei-Jie Zhang, Khalid Bo-Subait
Blood Advances. 2021-09-22 - 4 citationsNovel FGFR3 rearrangement t(4;22)(p16;q11.2) in a patient with chronic lymphocytic leukemia/small lymphocytic lymphomaJan Cerny, Hongbo Yu, Patricia M. Miron
Annals of Hematology. 2013-04-13
Books/Book Chapters
Lectures
- High Dose Mitoxantrone Based “5+1” Induction Chemotherapy Regimen in Newly Diagnosed Acute Myeloid Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Hematopoeitic Cell Transplant - Comorbidity Index (HCT-CI) Score Is a Useful Tool for Predicting Induction Mortality and Overall Survival in Newly Diagnosed Acute Myel...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Lupus Center at UMass Chan Investigates CAR T-cell Therapy for Severe or Unresponsive Lupus NephritisJuly 15th, 2024
Professional Memberships
- Member
Other Languages
- Czech
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
